Bayer’s Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.
Makary pushes for IRB reforms to catch China’s speedy trial starts
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with



